All In Biotech

Drug Trial Radar · NCT05549505

A Trial Using ARV-471 or Anastrozole in Post-Menopausal Women With Breast Cancer Prior to Surgery

An Open-label, Randomized, Non-comparative Phase 2 Study of ARV-471 or Anastrozole in Post-menopausal Women With ER+/HER2- Breast Cancer in the Neoadjuvant Setting

Last checked: Nov 19, 2026Latest source record: Aug 29, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 152 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

152

Actual

Start

Feb 15, 2023

Primary completion

Jul 13, 2024

Study completion Jul 25, 2024

Sponsor

Lead sponsor
Arvinas Inc.Industry
Sponsor type
Industry
Collaborators
Pfizer
First posted
Sep 22, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial is a Phase 2 neoadjuvant study evaluating ARV-471 or anastrozole in post-menopausal women with estrogen receptor positive/ human epidermal growth factor receptor 2 (ER+/HER2)- localized breast cancer.

Conditions

  • Breast Cancer

Interventions

  • ARV-471Drug

    100 mg tablet

  • AnastrozoleDrug

    1 mg tablet

  • Surgical resection of breast tumorProcedure

    Surgical resection approximately 5.5 months after starting treatment (C6D18 ± 14 days)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent Reduction in Ki-67 Expression From Baseline to Day 15 in Tumor BiopsiesTime frame: Baseline (during screening, prior to Day 1) and Day 15

Locations

49 sites in 4 countries. Site status is shown where the registry gives one.

  • Clinical Trial Site

    Springdale, Arkansas

  • Clinical Trial Site

    Los Angeles, California

  • Clinical Trial Site

    Torrance, California

  • Clinical Trial Site

    Van Nuys, California

  • Clinical Trial Site

    Fort Lauderdale, Florida

  • Clinical Trial Site

    Fort Myers, Florida

  • Clinical Trial Site

    Orlando, Florida

  • Clinical Trial Site

    West Palm Beach, Florida

  • Clinical Trial Site

    Iowa City, Iowa

  • Clinical Trial Site

    Springfield, Massachusetts

  • Clinical Trial Site

    St Louis, Missouri

  • Clinical Trial Site

    Nashville, Tennessee

  • Clinical Trial Site

    Tacoma, Washington

  • Clinical Trial Site

    Batumi, Georgia

  • Clinical Trial Site

    Tbilisi, Georgia

  • Clinical Trial Site

    Tbilisi, Georgia

  • Clinical Trial Site

    Tbilisi, Georgia

  • Clinical Trial Site

    Augsburg, Germany

  • Clinical Trial Site

    Berlin, Germany

  • Clinical Trial Site

    Bonn, Germany

  • Clinical Trial Site

    Bottrop, Germany

  • Clinical Trial Site

    Chemnitz, Germany

  • Clinical Trial Site

    Dresden, Germany

  • Clinical Trial Site

    Erlangen, Germany

  • Clinical Trial Site

    Essen, Germany

  • Clinical Trial Site

    Essen, Germany

  • Clinical Trial Site

    Esslingen am Neckar, Germany

  • Clinical Trial Site

    Mannheim, Germany

  • Clinical Trial Site

    Paderborn, Germany

  • Clinical Trial Site

    Alicante, Spain

  • Clinical Trial Site

    Barcelona, Spain

  • Clinical Trial Site

    Barcelona, Spain

  • Clinical Trial Site

    Barcelona, Spain

  • Clinical Trial Site

    Castelló, Spain

  • Clinical Trial Site

    Córdoba, Spain

  • Clinical Trial Site

    Granada, Spain

  • Clinical Trial Site

    Granada, Spain

  • Clinical Trial Site

    Lleida, Spain

  • Clinical Trial Site

    Madrid, Spain

  • Clinical Trial Site

    Madrid, Spain

Showing 40 of 49 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.